ModernMedicine Resource Center More Topics

Video

Testosterone Therapy and Cardiovascular Risk

Dr. Abraham Morgentaler, an Associate Clinical Professor of Urology at Harvard Medical School, explores and clarify in the February 2015 issue of Mayo Clinic Proceedings, the value of testosterone therapy in men, and in particular the issue of cardiovascular risk.

The Lowdown on Low T

Injected TRT earns high marks for safety, effectiveness
Injected TRT earns high marks for safety, effectivenessA newly published review suggests that age-related testosterone deficiency treatment with intramuscular injections of testosterone replacement therapy offers health benefits and lower cardiovascular risk compared to testosterone replacement by patch or gel.
Studies examine risk factors for low, high TA handful of new studies reveal new information about risk factors for both low and high testosterone as well as the potential risks associated with each.
Testosterone nasal gel shows safety, efficacyA new testosterone nasal gel (Natesto) is safe and efficacious, according to phase III data presented at the Endocrine Society annual meeting in San Diego.
FDA moves to change TRT product labelingThe FDA acted on recommendations from one of its advisory committees by requiring manufacturers of testosterone therapies to make label changes that restrict the drugs’ usage.
TRT: Review finds no evidence of cardiovascular risk
TRT: Review finds no evidence of cardiovascular riskA literature review has found no evidence that testosterone therapy increases cardiovascular risk.
2014 Year in Review: Men's Health
2014 Year in Review: Men's HealthUrology Times continues its "Year in Review" series with a look at the most-read men's health articles of 2014.
Companies acquire rights to low T, IC drugs
Companies acquire rights to low T, IC drugsIn separate actions, two pharmaceutical makers have acquired the rights to a novel testosterone agent and a patented formulation for interstitial cystitis/painful bladder syndrome.
European agencies follow FDA lead on T, CV risk
European agencies follow FDA lead on T, CV riskThe European Medicines Agency has issued new recommendations regarding testosterone replacement therapy after reviewing the cardiovascular risks of TRT. The recommendations were endorsed by a regulatory body that is responsible for the marketing authorization of drugs throughout Europe.
Study: No increase in CV risk with testosterone
Study: No increase in CV risk with testosteroneTestosterone replacement therapy reduced men’s overall risks for death, nonfatal myocardial infarction, and stroke, as well as for death alone in a study presented at the American Heart Association Scientific Sessions in Chicago.
Alternatives to T therapy: Lessons from male infertility
Alternatives to T therapy: Lessons from male infertilityWhatever the exact mechanism of the increase in desire for testosterone replacement therapy in men, knowing the risks and benefits of testosterone and its alternatives are vital skills for today’s practicing urologist. This article will focus on alternatives to testosterone therapy.